Immune checkpoint blockers in patients with unresectable or metastatic thymic epithelial tumours: A meta-analysis

Jordi Remon,Guillermo Villacampa,Francesco Facchinetti,Massimo Di Maio,Florit Marcuse,Marcello Tiseo,Monique Hochstenbag,Lizza E.L. Hendriks,Benjamin Besse

European Journal of Cancer（2022）

引用 1|浏览0

暂无评分

摘要

•Immune checkpoint blockers strategy is feasible in pre-treated thymic carcinomas.•In this population, ICB achieve a RR of 18% and one-year OS of 67%.•Close monitoring of patients is strongly advised to detect severe immune-toxicity.

查看译文

关键词

Immune checkpoint blockers,Advanced thymic epithelial tumours,Pembrolizumab,Nivolumab,Atezolizumab,Avelumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要